中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 35 Issue 5
May  2019
Turn off MathJax
Article Contents

Resistance-associated variants in the non-structural protein 5B region in patients with hepatitis C virus genotype 1b infection in Guangxi, China

DOI: 10.3969/j.issn.1001-5256.2019.05.012
Research funding:

 

  • Received Date: 2019-01-14
  • Published Date: 2019-05-20
  • Objective To investigate the incidence rate of resistance-associated variants ( RAVs) in the non-structural protein 5B (NS5B) region in patients with hepatitis C virus ( HCV) genotype 1b ( GT1b) infection in Guangxi, China, as well as its difference between male and female patients. Methods A total of 60 previously untreated patients with HCV GT1b infection who were admitted to The First Affiliated Hospital of Guangxi Medical University from April 2016 to September 2018 were enrolled. Their baseline serum samples were collected. The NS5B region fragments were amplified by nested PCR and gene sequencing was performed, and then the sequencing results were compared with standard strains in GeneBank. The t-test was used for comparison of age, HCV RNA, alanine aminotransferase ( ALT) , and aspartate aminotransferase ( AST) between male and female patients, and the Fisher's exact test was used for comparison of mutation rate of drug-resistance sites. Results Of all 60 patients, 55 obtained the complete sequence information of the NS5B region, and the incidence rate of RAVs in the NS5B region was 96. 3%. C316 ( 94. 5%) , A338 ( 70. 9%) , and T19 ( 74. 5%) were the main mutation sites, and multisite mutations such as C316 + T19 and C316 + T19 + A338 were observed. There was no significant difference in the incidence rate of RAVs between male patients and female patients [95. 8% ( 23/24) vs 96. 8% ( 30/31) , P = 1. 000]. Conclusion Patients with HCV GT1b infection in Guangxi have a high incidence rate of RAVs in the NS5B region, with both single-site and multisite mutations.There is no significant difference in the incidence rate of RAVs between male and female patients.

     

  • loading
  • [1] XIE L, HAO P, WU RH, et al. Establishment and application of a database for hepatitis C virus NS3/4A protease inhibitors and their drug resistance data[J]. J Clin Hepatol, 2018, 34 (9) :1884-1890. (in Chinese) 谢磊, 郝沛, 吴瑞红, 等. HCV NS3/4A蛋白酶抑制剂药物及其耐药信息数据库的建立和应用[J].临床肝胆杂志, 2018, 34 (9) :1884-1890.
    [2] MESSINA JP, HUMPHREYS I, FLAXMAN A, et al. Global distribution and prevalence of hepatitis C virus genotypes[J].Hepatology, 2015, 61 (1) :77-87.
    [3] PAWLOTSKY JM, NEGRO F, AGHEMO A, et al. EASL Recommendations on treatment of hepatitis C 2018[J]. Hepatology, 2018, 69 (2) :461-511.
    [4] MOHD HANAFIA K, GROEGER J, FLAXMAN AD, et al. Global epidemiology of hepatitis C virus infection:New estimates of age-specific antibody to HCV seroprevalence[J]. Hepatology, 2013, 57 (4) :1333-1342.
    [5] TANG W, SU MH, JIANG JN, et al. Epidemiological characteristics and genotype distribution of hepatitis C virus in Guangxi[J]. World Chin J Dig, 2014, 22 (9) :1300-1306. (in Chinese) 唐维, 苏明华, 江建宁, 等.广西地区丙型肝炎病毒的基因型分布与流行病学特征[J].世界华人消化杂志, 2014, 22 (9) :1300-1306.
    [6] MANNS M, MARCELLIN P, POORDAD F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1infection (QUEST-2) :A randomised, double-blind, placebo-controlled phase 3 trial[J]. Lancet, 2014, 384 (9941) :414-426.
    [7] DONALDSON EF, HARRINGTON PR, O'REAR JJ, et al. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir[J]. Hepatology, 2015, 61 (1) :56-65.
    [8] QUAN M, XING HC. Effects of hepatitis C virus resistance associated variants on the efficacy of direct-acting antiviral agents[J/CD]. Chin J Liver Dis:Electronic Edit, 2018, 10 (3) :32-36. (in Chinese) 全敏, 邢卉春.丙型肝炎病毒耐药相关变异对直接抗病毒药物疗效的影响[J/CD].中国肝脏病杂志:电子版, 2018, 10 (3) :32-36.
    [9] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guide line of prevention and treatment for chronic hepatitis C:A 2015 update[J]. J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.
    [10] AN ZY, DING Y, DOU XG, et al. Selection and evaluation of treatment regimens with direct-acting antiviral agents for patients with chronic hepatitis C in the real world in China[J]. J Clin Hepatol, 2018, 34 (2) :233-237. (in Chinese) 安子英, 丁洋, 窦晓光, 等.我国慢性丙型肝炎患者真实世界中直接抗病毒药物治疗方案的选择与评价[J].临床肝胆杂志, 2018, 34 (2) :233-237.
    [11] LEMM JA, LIU M, GENTLES RG, et al. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase[J]. Antimicrob Agents Chemother, 2014, 58 (6) :3485-3495.
    [12] DVORY-SOBOL H, VOITENLEITNER C, MABERY E, et al.Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase[J]. Antimicrob Agents Chemother, 2014, 58 (11) :6599-6606.
    [13] SUN D, DAI M, SHEN S, et al. Analysis of naturally occurring resistance-associated variants to NS3/4A Protein inhibitors, NS5A protein inhibitors, and NS5B polymerase inhibitors in patients with chronic hepatitis C[J]. Gene Expression, 2018, 18 (1) :63-69.
    [14] CHARLTON M, GANE E, MANNS MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation[J]. Gastroenterology, 2015, 148 (1) :108-117.
    [15] ALVES R, QUEIROZ ATL, PESSOA MG, et al. The presence of resistance mutations to protease and polymerase inhibitors in hepatitis C virus sequences from the Los Alamosdatabank[J]. J Viral Hepat, 2013, 20 (6) :414-421.
    [16] WANG Y, RAO HY, XIE XW, et al. Direct-acting antiviral agents resistance-associated polymorphisms in chinese treatment-nave patients infected with genotype 1b hepatitis C virus[J]. Chin Med J (Engl) , 2015, 128 (19) :2625-2631.
    [17] JI H, KOZAK RA, BIONDI MJ, et al. Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282drug resistance mutations[J]. Virology, 2015, 477:1-9.
    [18] BARTELS DJ, SULLIVAN JC, ZHANG EZ, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment[J]. J Virol, 2013, 87 (3) :1544-1553.
    [19] HALFON P, SARRAZIN C. Future treatment of chronic hepatitis C with direct acting antivirals:Is resistance important?[J].Liver Int, 2012, 32 (Suppl 1) :79-87.
    [20] VOITENLEITNER C, CROSBY R, WALKER J, et al. In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor[J]. Antimicrob Agents Chemother, 2013, 57 (11) :5216-5224.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1532) PDF downloads(297) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return